Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey-Reference-Cited by-同舟云学术

Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey

Published:2023-05-24 Issue:1 Volume:26 Page:720-730
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Tugay Deniz¹^ORCID,Top Mehmet²,Aydin Ömür³^ORCID,Bavbek Sevim³,Damadoğlu Ebru⁴^ORCID,Öner Erkekol Ferda⁵^ORCID,Koca Kalkan Ilkay⁶,Kalyoncu A. Fuat⁴^ORCID,Karakaya Gül⁴,Oğuzülgen I. Kivilcim⁷^ORCID,Türktaş Haluk⁷,Abraham Ivo⁸^ORCID

Affiliation:

1. Rights of Patients Department, Ankara City Hospital, Ankara, Turkey

2. Department of Health Management, Faculty of Economics and Administrative Sciences, Hacettepe University, Ankara, Turkey

3. Division of Immunology and Allergy, Department of Pulmonary Diseases, School of Medicine, Ankara University, Ankara, Turkey

4. Division of Immunology and Allergy, Department of Pulmonary Diseases, School of Medicine, Hacettepe University, Ankara, Turkey

5. Division of Immunology and Allergy, Department of Pulmonary Diseases, School of Medicine, Yildirim Beyazit University, Ankara, Turkey

6. Division of Immunology and Allergy, Department of Pulmonary Diseases, Ankara Atatürk Sanatorium Research and Training Hospital, Ankara, Turkey

7. Department of Pulmonary Diseases, School of Medicine, Gazi University, Ankara, Turkey

8. Center for Health Outcomes and PharmacoEconomic Research, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, AZ, USA

Funder

The Scientific and Technological Research Council

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2209417

Reference47 articles.

1. Global Initiative for Asthma. Available from: https://ginasthma.org/

2. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015;GBD 2015 Chronic Respiratory Disease Collaborators;Lancet Respir Med,2007

3. Üner S, Balcılar M, Ergüder T, editors. Türkiye Hanehalki Sağlik Araştirmasi Bulaşici Olmayan Hastaliklarin Risk Faktörleri. Ankara: Dünya Sağlık Örgütü Avrupa Bölge Ofisi, T.C. Sağlık Bakanlığı; 2018.

4. Allergy & Asthma Network. How severe is my asthma: classifying asthma severity. Available from: https://allergyasthmanetwork.org/news/how-severe-is-my-asthma/

5. The Prevalence of Severe Asthma and Low Asthma Control Among Danish Adults

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost effectiveness of omalizumab for severe asthma in Colombia;Journal of Asthma;2023-10-10

2. Real-Life Data on the Use of Omalizumab in Patients with Severe Asthma and Chronic Urticaria and Mepolizumab in Patients with Severe Asthma: A Retrospective Study;OSMANGAZİ JOURNAL OF MEDICINE;2023-09-26